GlutenSpA trial: protocol for a randomised double-blind placebo-controlled trial of the impact of a gluten-free diet on quality of life in patients with axial spondyloarthritis

Marion Couderc, Bruno Pereira, Thierry Schaeverbeke, Thierry Thomas, Roland Chapurlat, Philippe Gaudin, Jacques Morel, Maxime Dougados, Martin Soubrier, Marion Couderc, Bruno Pereira, Thierry Schaeverbeke, Thierry Thomas, Roland Chapurlat, Philippe Gaudin, Jacques Morel, Maxime Dougados, Martin Soubrier

Abstract

Introduction: Subclinical intestinal inflammation and gut dysbiosis have been reported in patients with spondyloarthritis (SpA). In common practice, rheumatologists are increasingly confronted with patients with inflammatory rheumatism who are on gluten-free diets (GFDs), despite the lack of reliable data from controlled studies. This study aims to determine the impact of a GFD on the quality of life of patients with axial SpA.

Methods and analysis: The GlutenSpA study is a 24-week, randomised, double-blinded, placebo-controlled, multicentre trial. Patients with axial SpA (n=200) will follow a 16-week GFD and be randomly assigned (1:1) to an experimental or control arm. In the experimental arm with receive at least 6 gluten-free breads per day + 200 g of gluten-free penne pasta per week + 6 rice flavour capsules per day. The control arm will receive at least 6 gluten-containing breads per day + 200 g of gluten-containing penne pasta per week + 6 vital gluten-containing capsules per day. The primary end-point is the variation in Assessment of SpondyloArthritis International Society-Health Index (ASAS-HI) questionnaire between week 16 and baseline. A second open-label period of 8 weeks will follow the intervention period, during which the patient will be free to decide whether they will follow the GFD. The secondary outcomes comprise several patient-reported outcomes (SpA activity (Bath Ankylosing Spondylitis Disease Activity Index)), fatigue (Functional Assessment of Chronic Illness Therapy), depression (Hospital Anxiety and Depression Scale), functional disability index (Bath Ankylosing Spondylitis Functional Index)), variations in body mass index and Homeostasis Model Assessment Index and variations in the abundance and type of bacterial species found in the gut microbiota for a subgroup of patients (n=40). The data will be analysed using the intention-to-treat principle.The regional ethics committee (CPP Nord-ouest IV) has approved the study (IDRCB 2018-A00309-46). The results of the trial will be submitted for publication in peer-reviewed journals. The authors have no relationship that may have influenced the submitted work.

Trial registration number: NCT04274374.

Keywords: inflammatory bowel disease; nutrition & dietetics; rheumatology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
GlutenSpa study diagram.

References

    1. López-Medina C, Moltó A. Update on the epidemiology, risk factors, and disease outcomes of axial spondyloarthritis. Best Pract Res Clin Rheumatol 2018;32:241–53. 10.1016/j.berh.2018.10.006
    1. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017;390:73–84. 10.1016/S0140-6736(16)31591-4
    1. Mielants H, Veys EM, Cuvelier C, et al. . The evolution of spondyloarthropathies in relation to gut histology. II. histological aspects. J Rheumatol 1995;22:2273–8.
    1. Mielants H, De Vos M, Cuvelier C, et al. . The role of gut inflammation in the pathogenesis of spondyloarthropathies. Acta Clin Belg 1996;51:340–9. 10.1080/22953337.1996.11718528
    1. De Vos M, Mielants H, Cuvelier C, et al. . Long-Term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996;110:1696–703. 10.1053/gast.1996.v110.pm8964393
    1. Van Praet L, Van den Bosch FE, Jacques P, et al. . Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013;72:414–7. 10.1136/annrheumdis-2012-202135
    1. Jacques P, Elewaut D. Joint expedition: linking gut inflammation to arthritis. Mucosal Immunol 2008;1:364–71. 10.1038/mi.2008.24
    1. Klingberg E, Carlsten H, Hilme E, et al. . Calprotectin in ankylosing spondylitis--frequently elevated in feces, but normal in serum. Scand J Gastroenterol 2012;47:435–44. 10.3109/00365521.2011.648953
    1. Matzkies FG, Targan SR, Berel D, et al. . Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther 2012;14:R261. 10.1186/ar4106
    1. Klingberg E, Strid H, Ståhl A, et al. . A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther 2017;19:21. 10.1186/s13075-017-1223-2
    1. Moreno Martínez MJ, Moreno Ramos MJ, Linares Ferrando LF. Relationship between fecal calprotectin, anti-Saccharomyces cerevisiae antibodies and other markers of disease activity in patients with spondyloarthritis. Reumatol Clin 2019;15:360–2. 10.1016/j.reumae.2017.11.005
    1. Dignass AU. Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 2001;7:68–77. 10.1097/00054725-200102000-00014
    1. Lopetuso LR, Scaldaferri F, Bruno G, et al. . The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. Eur Rev Med Pharmacol Sci 2015;19:1068–76.
    1. Strati F, Cavalieri D, Albanese D, et al. . New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome 2017;5:24. 10.1186/s40168-017-0242-1
    1. El-Chammas K, Danner E. Gluten-Free diet in nonceliac disease. Nutr Clin Pract 2011;26:294–9. 10.1177/0884533611405538
    1. Breban M. Gut microbiota and inflammatory joint diseases. Joint Bone Spine 2016;83:645–9. 10.1016/j.jbspin.2016.04.005
    1. Taurog JD, Maika SD, Satumtira N, et al. . Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev 1999;169:209–23. 10.1111/j.1600-065x.1999.tb01317.x
    1. Costello M-E, Ciccia F, Willner D, et al. . Brief report: intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol 2015;67:686–91. 10.1002/art.38967
    1. Gevers D, Kugathasan S, Denson LA, et al. . The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014;15:382–92. 10.1016/j.chom.2014.02.005
    1. Varoquier C, Salmon J-H, Danion F, et al. . Les effets des régimes et des stratégies diététiques dans La polyarthrite rhumatoïde. Rev Rhum 2015;82:283–90. 10.1016/j.rhum.2014.11.016
    1. Carmody RN, Gerber GK, Luevano JM, et al. . Diet dominates host genotype in shaping the murine gut microbiota. Cell Host Microbe 2015;17:72–84. 10.1016/j.chom.2014.11.010
    1. Uranga JA, López-Miranda V, Lombó F, et al. . Food, nutrients and nutraceuticals affecting the course of inflammatory bowel disease. Pharmacol Rep 2016;68:816–26. 10.1016/j.pharep.2016.05.002
    1. Wacklin P, Laurikka P, Lindfors K, et al. . Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet. Am J Gastroenterol 2014;109:1933–41. 10.1038/ajg.2014.355
    1. Makharia A, Catassi C, Makharia GK. The overlap between irritable bowel syndrome and non-celiac gluten sensitivity: a clinical dilemma. Nutrients 2015;7:10417–26. 10.3390/nu7125541
    1. Isasi C, Stadnitsky A, Casco F, et al. . Non-Celiac gluten sensitivity and chronic refractory low back pain with spondyloarthritis features. Med Hypotheses 2020;140:109646. 10.1016/j.mehy.2020.109646
    1. Albert C, Brocq O, Berthier R, et al. . Enquête sur l’utilisation d’un régime d’éviction auprés des patients atteints d’un rhumatisme inflammatoire chronique : propos de 382 patients. Paris: 28eme congrès de Rhumatologie, 2015.
    1. Kiltz U, van der Heijde D, Boonen A, et al. . Measurement properties of the ASAS health index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis 2018;77:1311–7. 10.1136/annrheumdis-2017-212076
    1. Rudwaleit M, van der Heijde D, Landewé R, et al. . The assessment of spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25–31. 10.1136/ard.2010.133645
    1. Kiltz U, van der Heijde D, Boonen A, et al. . Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS health index and the environmental item set: translation and cross-cultural adaptation into 15 languages. RMD Open 2016;2:e000311. 10.1136/rmdopen-2016-000311

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel